Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume Increase on Strong Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw unusually-strong trading volume on Friday following a stronger than expected earnings report. Approximately 1,629,126 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 1,791,944 shares.The stock last traded at $99.7090 and had previously closed at $85.76.

The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same period last year, the firm earned $1.54 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

Analyst Ratings Changes

Several research analysts have issued reports on HALO shares. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $89.60.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the sale, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 72,477 shares of company stock valued at $5,102,643. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Mizuho Markets Americas LLC grew its stake in Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Paragon Capital Management Inc. acquired a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $1,273,000. Hussman Strategic Advisors Inc. lifted its holdings in Halozyme Therapeutics by 66.7% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock worth $3,533,000 after buying an additional 21,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Halozyme Therapeutics by 19,326.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after buying an additional 85,036 shares during the last quarter. Finally, Assetmark Inc. grew its position in shares of Halozyme Therapeutics by 11.9% in the 4th quarter. Assetmark Inc. now owns 137,415 shares of the biopharmaceutical company’s stock worth $9,248,000 after acquiring an additional 14,568 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 14.4%

The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company has a market cap of $11.64 billion, a price-to-earnings ratio of 35.31, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85. The firm has a 50-day moving average price of $75.74 and a 200 day moving average price of $71.25.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.